InvestorsHub Logo
Followers 104
Posts 16409
Boards Moderated 0
Alias Born 06/24/2014

Re: None

Monday, 07/17/2023 7:05:11 AM

Monday, July 17, 2023 7:05:11 AM

Post# of 55
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BBIO News